Impact of White-coat Hypertension on Microvascular Complications in Type 2 Diabetes Mellitus

  1. Caroline K. Kramer, MD (ckkramer{at}terra.com.br),
  2. Cristiane B. Leitão, MD, PhD,
  3. Luís H. Canani, MD, PhD and
  4. Jorge L. Gross, MD, PhD
  1. Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    Abstract

    Objective: To determine the impact of white-coat hypertension (WCH) on microvascular complications in type 2 diabetes mellitus (DM).

    Research Design and Methods: A cross-sectional study was conducted in normotensive and WCH subjects selected from a cohort of 319 type 2 DM patients. Normotension was defined by office blood pressure (BP) <140/90 mmHg and daytime BP in ambulatory BP monitoring (ABPM) <135/85 mmHg. WCH was defined as office BP ≥140/90 mmHg and daytime BP on ABPM <135/85 mmHg. Subjects were evaluated for diabetic nephropathy (DN; 24 h urinary albumin excretion rate) and diabetic retinopathy (DR; classified according to the Global Diabetic Retinopathy Group)

    Results: Forty-six type 2 DM patients had WCH (14.4%; age 56.6; 45.3% men) and 117, normotension (36.6%; age 55.8; 37.5% men). These groups did not differ in clinical and main laboratory characteristics. Systolic ABPM (24-h: 124.7±6.7 vs. 121.0±8.5 mmHg, P=0.01 and daytime: 126.6±7.2 vs. 123.2±8.2 mmHg, P=0.01) and BP loads were higher in WCH subjects than in the normotensive ones. WCH was associated with an increased risk for macroalbuminuria (OR 4.9, 95%CI 1.3-18.7, P=0.01). On multivariate analysis models, WCH was associated with macroalbuminuria (OR 2.0 95%CI 1.3-3.2, P=0.02) and increased the risk for both non-proliferative and proliferative DR (OR 2.7, 95%CI 1.2-6.6, P=0.02 for any degree of DR) after adjustments for confounding factors.

    Conclusions: Type 2 DM patients with WCH have an increased risk for DR and DN. Therefore, WCH should not be considered a harmless condition and treatment should be considered.

    Footnotes

      • Received July 12, 2008.
      • Accepted August 22, 2008.